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1 Present address: Maltepe Ersoy Hospital, Istanbul, Turkey.Ozlen Rodop Ozgur a,⇑; Yelda Ozkurt b; Zeynep Kulekci c; Tufan Evciman b,1AbstractPurpose: To assess the safety and efficiency of combined phacoemulsification (PHACO) surgery and intravitreal triamcinolone
(IVTA) injection with or without macular grid laser photocoagulation in patients with cataract and diabetic macular edema.
Material and methods: This prospective study included 41 eyes of 36 diabetic patients with cataract and coexisting clinically
significant macular edema (CSME). After PHACO and IVTA injection eyes were divided into two groups: the laser and IVTA group
(Group 1) and only IVTA group (Group 2). Preoperative and postoperative best corrected visual acuity (BCVA), central macular
thickness (CMT), and intraocular pressure (IOP) were recorded. Paired sample t-test was used to compare data in the groups
and C square test for qualitative variables.
Results: Postoperative BCVA was significantly higher than the initial BCVA during the follow-up period in both groups (p < 0.01).
The BCVA 6 months after surgery was significantly higher in group 1 than in group 2 (p < 0.01). There was no statistically significant
difference in IOP between two groups preoperatively and postoperatively during the follow-up period (p > 0.05). There was no sta-
tistically significant difference between both groups in mean CMT preoperatively and 2nd week, 2nd month and 3rd month after
surgery (p > 0.05). The mean CMT 6 months after surgery was statistically significantly lower in group 1 than in group 2 (p < 0.01).
Conclusions: PHACO surgery combined with IVTA injection improves BCVA and provides a decrease in CMT in diabetic patients
with CSME. Additional macular grid laser photocoagulation after surgery helps to preserve this improvement in BCVA and
decrease in CMT.
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Diabetic macular edema is characterized by intraretinal
and subretinal accumulations of fluid, resulting principally
from retinal vascular leakage and is the main cause of visualimpairment in diabetic patients.1,2 Cataract is another ocular
complication of diabetes and 20% of all cataract surgeries are
performed on diabetics.3 Macular edema at the time of
surgery has been suggested to be risk factor for poorer visual
outcome. Royal College of Ophthalmologists’ guidelines fore:
al.com
ail.com
Table 1. Preoperative clinical characteristics of the groups.
Group I Group II p
Mean ± SD Mean ± SD
aAge 66.71 ± 5.14 66.05 ± 5.06 0.679
aHbA1c 6.60 ± 0.34 6.70 ± 0.30 0.344
aDuration of DM 14.19 ± 3.93 13.90 ± 4.71 0.831
Number of patients n (%) n (%)
bSex Female 11 (52.4%) 11 (55.0%) 0.867
Male 10 (47.6%) 9 (45.0%)
a Student’s t test.
b C square test.
34 O.R. Ozgur et al.cataract surgery in diabetics state that if clinically significant
macular edema (CSME) is identified before surgery, it should
be treated at least 12 weeks prior to surgery.4,5 But it is com-
mon to see patients with significant cataract that impedes the
treatment or even diagnosis of CSME. Some studies have
found an increased risk of retinopathy progression and in par-
ticular macular edema exacerbation with cataract surgery.
However, some patients with diabetic CSME are refractory
to conventional photocoagulation.6–11
Triamcinolone acetonide is a corticosteroid with anti-
inflammatory and antiangiogenic properties. Intravitreal
injection of triamcinolone (IVTA) injection is an alternative
for treating CSME especially in patients with advanced
cataract.4,5,12,13
In this study, we aimed to assess the safety and efficiency
of combined phacoemulsification (PHACO) surgery and IVTA
injection with or without macular grid laser photocoagulation
in patients with cataract and diabetic macular edema.Material and methods
This prospective study included 41 eyes of 36 multiethnic
Turkish diabetic patients with cataract and coexisting clini-
cally significant macular edema (CSME). All patients were
diagnosed with CSME according to the ETDRS criteria. All
patients filled up informed consent form. The study was car-
ried out according to the tenets of the Declaration of Hel-
sinki. Institutional Review Board approval has been
obtained. The age of the patients ranged between 54 and
79 years (mean age 66.39). Twenty-two of them were female
(53.7%) and 19 were (46.3%) male. HbA1c at the time of sur-
gery differed from 6.2 to 7.3 (HbA1c 6.65). The duration of
diabetes mellitus differed from 6 to 23 years (mean
14.05 years). Preoperative clinical characteristics of the
groups are summarized in Table 1. As seen in Table 1 there
is no statistically significant difference in patient characteris-
tics between the two groups (p > 0.05).
At baseline examination, best corrected visual acuity
(BCVA), central macular thickness, and intraocular pressure
(IOP) were recorded. Patients who had visually significant cat-
aract and either diffuse central macular edema of at least
250 lm demonstrated by optic coherence tomography
(OCT) or persistent diabetic macular edema unresponsive
to laser treatment were included in the study. None of the
patients had received any previous intravitreal injection.
Exclusion criteria were a history of either ocular hypertension
or glaucoma, previous ocular trauma or surgery, and intraop-
eratively complicated PHACO surgery with vitreous loss.
After surgery the enrolled eyes were divided into two
groups, the laser and IVTA group (Group 1) and the only IVTA
group (Group 2). Patients in group 1 underwent IVTA,
PHACO surgery and macular grid photocoagulation 4 weeks
after the surgery. Patients in group 2 underwent only IVTA
and PHACO surgery.
Phacoemulsification and in-the-bag intraocular lens
implantation were performed under topical anesthesia using
0.5% proparacaine HCl drop with a self-sealing corneal tun-
nel. At the end of cataract surgery 4 mg in 0.1 ml of preserva-
tive free triamcinolone acetonide (Kenacort A, Bristol Myers
Squibb) was injected via the inferotemporal pars plana
(3.5 mm from limbus), using 27 G needle. Patients were
instructed to semi-sitting position in the immediate postop-erative to avoid macular staining by the Triamcinolone. Post-
operatively, 1% prednisolone acetate eye drop and 0.5%
ofloxacin eye drop were applied four times daily 1 week,
and then tapered weekly over 3-week period.
Grid laser photocoagulation 4 weeks after surgery was
applied only in group 1 under topical anesthesia with fundus
contact lens. The laser spots were applied with argon green
wavelength, duration of 100 msn, diameter of 100 lm, and
the power increased from 75 mW to produce a mild gray
burn on all areas of capillary nonperfusion and retinal thicken-
ing based on the findings of fundus fluorescein angiography
and OCT.
Patients were examined 1 day, 1 week, 2 weeks, 2 months,
3 months and sixth months after surgery. The response to
treatment was monitored functionally by BCVA assessment
by Snellen chart and anatomically measuring the central mac-
ular thickness by OCT. Biomicroscopic examinations and IOP
monitoring were performed on each visit. Topical antiglauco-
matous treatment was initiated if IOP was more than
21 mmHg.
Statistical analysis was performed. The results were ana-
lyzed with NCSS 2007&PASS 2008 Statistical Software (Utah,
USA). Student’s t test was used for comparing quantitative
data and also for comparing the data of two groups. Paired
sample t test was used to compare data in the group and
C square test for qualitative variables. Results were 95% reli-
able and the value of p < 0.05 was considered as significant.Results
There was no statistically significant difference in BCVA
between two groups preoperatively and 1 day, 1 week,
2 weeks, 2 months and 3 months postoperatively (p > 0.05)
(Table 2). The BCVA at the 1st day, 1st week, 2nd week,
2nd month, 3rd month and 6th month visit after surgery
was significantly higher than the initial BCVA in both groups
(p < 0.01). On the other hand the BCVA 6 months after sur-
gery was significantly higher in group 1 than in group 2
(p < 0.01) (Table 2 and Fig. 1).
There was no statistically significant difference in IOP
between two groups preoperatively and 1 day, 1 week,
2 weeks, 2 months, 3 months and 6 months postoperatively
(p > 0.05). The differences between preoperative IOP and
all postoperative intervals until 6 months were not statistically
significant in both groups (p > 0.05) (Tables 3 and 4).
There was no statistically significant difference between
both groups in mean CMT preoperatively and 2nd week,
2nd month and 3rd month after surgery (p > 0.05). The mean
CMT 6 months after surgery was statistically significantly
lower in group 1 than in group 2 (p < 0.01) (Table 5).
Table 5. Evaluation of optic coherence tomography (OCT) between two
groups.
OCT Group I Group II p
Mean ± SD Mean ± SD
Preoperative 455.66 ± 57.09 456.85 ± 56.90 0.947
2nd week 261.42 ± 52.06 258.15 ± 61.21 0.854
2nd month 272.76 ± 62.81 276.50 ± 56.94 0.843
3rd month 284.71 ± 56.96 280.05 ± 56.66 0.794
6th month 291.76 ± 52.79 433.30 ± 77.29 0.001**
Student’s t test.
** p < 0.01.
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Figure 1. Progression of best corrected visual acuity (BCVA).
Table 4. Evaluations of IOP inside the groups.
IOP Group I
Mean ± SD
Group
I p
Group II
Mean ± SD
Group
II p
Preoperative –
1st day
0.09 ± 3.12 0.890 0.95 ± 3.73 0.269
Preoperative –
1st week
0.71 ± 5.61 0.566 0.70 ± 2.75 0.270
Preoperative –
2nd week
0.14 ± 4.57 0.888 0.70 ± 6.16 0.617
Preoperative –
2nd month
0.04 ± 2.78 0.938 1.45 ± 3.57 0.086
Preoperative –
3rd month
0.04 ± 3.30 0.948 0.10 ± 3.37 0.896
Preoperative –
6th month
0.23 ± 4.06 0.791 0.40 ± 4.25 0.679
Paired sample t test, IOP: intraocular pressure.
Table 2. Evaluation of best corrected visual acuity (BCVA).
BCVA Group I Group II p*
Mean ± SD Mean ± SD
Preoperative 0.17 ± 0.10 0.19 ± 0.10 0.561
1st day 0.49 ± 0.15 0.45 ± 0.14 0.385
1st week 0.61 ± 0.17 0.59 ± 0.13 0.695
2nd week 0.61 ± 0.16 0.58 ± 0.15 0.512
2nd month 0.64 ± 0.12 0.58 ± 0.15 0.208
3rd month 0.64 ± 0.12 0.57 ± 0.15 0.140
6th month 0.60 ± 0.14 0.41 ± 0.11 0.001**
* Student’s t test.
** p < 0.01.
Table 3. Evaluation of IOP in group 1 and group 2.
IOP Group I Group II p
Mean ± SD Mean ± SD
Preop 16.04 ± 2.59 16.85 ± 2.53 0.324
1st day 15.95 ± 2.59 15.90 ± 2.10 0.944
1st week 16.76 ± 5.13 16.15 ± 2.71 0.639
2nd week 16.19 ± 4.36 17.55 ± 5.79 0.400
2nd month 16.00 ± 2.66 15.40 ± 2.56 0.467
3rd month 16.09 ± 2.30 16.95 ± 2.74 0.285
6th month 15.80 ± 2.76 16.45 ± 2.87 0.472
Student’s t test, IOP: intraocular pressure.
Management of cataract in patients with diabetic macular edema 35In Group 1; the CMT decreased from preoperative values
with statistically significant reduction at all postoperative
intervals until 6 months (p < 0.01). There was no statistically
significant difference in the mean CMT comparing the 2nd
week to 2nd month, 3rd month, 6th months after surgery
(p > 0.05), as well as comparing 2nd month to 3rd month,
6th month and comparing the 3rd month to 6th month after
surgery (p > 0.05). There was an acceptable decline in the
mean CMT with an average of 44.78% reduction at the 2nd
week, 39.35% reduction at the 2nd month, 36.34% reduction
at the 3rd month and 34.67% reduction at the 6th month. In
Group 2; the CMT decreased from preop values with statisti-
cally significant reduction at all postoperative intervals until
3 months (p < 0.01); but the difference in the mean CMT
between preoperative and postoperative 6th months was
not statistically significant (p > 0.05). The decrease in the
mean CMT in the 2nd week compared to 2nd month, 3rd
month and 6th month was high statistically significant
(p < 0.01). There was no statistically significant difference in
the mean CMT between 2nd month and 3rd month
(p > 0.05). Six months after surgery there was an increase in
the mean CMT compared to 2nd month and 3rd month which
was high statistically significant (p < 0.01). There was an aver-
age of 46.45% reduction in the mean CMT at the 2nd week,
41.87% reduction at the 2nd month, 41.21% reduction at the
3rd month and 2.24% at the 6th month (Table 6).
During the study period, 6 eyes had an increase in IOP.
Increment is to 28 mmHg, 26 mmHg, and 31 mmHg in 3 eyes
of Group 1 at 1st week and to 29 mmHg, 27 mmHg and
33 mmHg in 3 eyes of Group 2. Intraocular pressure was con-
trolled with topical antiglaucoma medication in these eyes.
No other complications including injection related complica-Table 6. Evaluation of optic coherence tomography (OCT) inside the
groups.
OCT Group I
Mean ± SD
Group
I p
Group II
Mean ± SD
Group
II p
Preoperative
– 2nd week
194.23 ± 72.08 0.001** 198.70 ± 77.95 0.001**
Preoperative
– 2nd
month
182.90 ± 66.18 0.001** 180.35 ± 73.53 0.001**
Preoperative
– 3rd
month
170.95 ± 61.71 0.001** 176.80 ± 75.77 0.001**
Preoperative
– 6th
month
163.90 ± 61.33 0.001** 23.55 ± 77.99 0.193*
Paired sample t test.
* p < 0.05.
** p < 0.01.
36 O.R. Ozgur et al.tions, vitreous hemorrhage, endophthalmitis, and retinal
detachment were encountered in this study.Discussion
Diabetic macular edema is characterized by intraretinal
and subretinal accumulations of fluid, resulting principally
from retinal vascular leakage.1,12 The development of macu-
lar edema is thought to involve breakdown of inner blood–
retina barrier with release of endogenous permeability fac-
tors by an ischemic retina.4,5,14
In this study, we assessed visual outcome and CMT after
the combination of phacoemulsification surgery and intravit-
real triamcinolone and subsequent grid laser photocoagula-
tion in patients with cataract and diabetic macular edema.
Significant cataract may impede the treatment and even diag-
nosis of CSME. Diabetic CSMO refractory to conventional
laser treatment methods is also a common problem.4,5 Previ-
ous studies suggest that diabetic patients with macular
edema at the time of cataract surgery have poorer visual out-
comes because of progression in retinopathy and maculopa-
thy.15–20 However short-time phacoemulsification surgery
with small self-sealed corneal incisions without iris trauma,
and in-the-bag implantation of intraocular lenses, in general
do not cause progression of diabetic retinopathy.19 In this
study we performed phacoemulsification and in-the-bag
intraocular lens implantation with a self-sealing corneal tun-
nel. Chung et al. studied the effect of phacoemulsification
on the progression of diabetic retinopathy and reported that
retinopathy progressed significantly more in the operated eye
and related to preoperative CSME and poor renal function.7
Somaiya et al. reported that postoperative BCVA of 6/12
was five times less likely in nonproliferative diabetic retinopa-
thy patients and 30 times less likely in proliferative diabetic
retinopathy patients compared to diabetic patients without
retinopathy.21 A number of other patient characteristics such
as increasing age, female sex, duration of diabetes mellitus,
poor glycemic control with Hemoglobin A 1C at the time of
surgery and moderate to severe retinopathy have been found
associated with poor prognosis after cataract surgery in dia-
betic patients.13,22,23 In our study 53.7% of our patients were
female, the mean HbA1c level at the time of surgery was 6.65,
and the mean duration of diabetes mellitus was 14.05 years.
Previous reports have demonstrated improvements in the
visual acuity and macular edema after IVTA in diabetic
patients.12,13,24–26 Triamcinolone acetonide, an intermediate
acting corticosteroid suspension with a depot effect lasting
up to 41 days in animal studies, inhibits or downregulates
inflammatory mediators such as prostaglandins and vascular
endothelial growth factor and reduces breakdown of the
blood–retinal barrier.4,5,27–31 Giving triamcinolone before
surgery as a separate procedure has the potential for progres-
sion of lens opacities which may impede laser photocoagula-
tion in CSME. Combining cataract surgery with IVTA rather
than giving triamcinolone before surgery as a separate proce-
dure avoided the potential for progression of lens opacities
and IOP elevation associated with intraocular steroids which
could have further interfered with retinopathy assessment.
Combining the two procedures reduces the patient’s poten-
tial risk of endophthalmitis from two separate intraocular epi-
sodes to one, while at the same time offering improvedpatient convenience.4,5,13 We had no cases of endophthalmi-
tis. All the surgeries were performed in the operating room
with full asepsis, topical povidone preoperatively. Studies
investigating the efficacy of IVTA have reported the preva-
lence of IOP elevations to be between 9% and 77%. The wide
range in prevalence may be because of varying definitions of
IOP increase, triamcinolone concentration and considering
time of increase in IOP.13,25,26,31–33 Similar to other studies
only six (14%) of 41 eyes developed an increased IOP of over
21 mmHg. The IOP was normalized by topical antiglaucoma-
tous agents.
Results from different studies indicate that cataract sur-
gery with injection of IVTA may be performed safely with sig-
nificant improvement in BCVA postoperatively.4,5,13,20,31 But
Ahmadabadi et al. reported injection of triamcinolone after
phacoemulsification had no effect on visual acuity.33 In our
study the BCVA during the 6 months of follow-up period
after a successful PHACO surgery was significantly higher
than the initial BCVA in both groups (p < 0.01). On the other
hand the mean BCVA 6 months after surgery was significantly
higher in group 1 than in group 2. Previous studies have
demonstrated that direct argon laser photocoagulation
applied to focally leaking micro-aneurysms and/or grid treat-
ment applied to areas of diffuse macular edema results in a
substantial reduction of the risk of visual loss in eyes with dia-
betic macular edema.12,14,34–38 Although the exact mecha-
nism underlying grid photocoagulation remains a matter of
some controversy, it may be attributable to the effects on
both endothelial cells of the retinal blood vessels and the reti-
nal pigment epithelial cells.12 Laser-induced changes in the
retinal pigment epithelium may also stimulate the repair of
endothelial cells in the inner blood–retinal barrier with subse-
quent resolution of the macular edema.12,36–38 Some authors
have suggested that grid photocoagulation enhances the
debridement of disordered retinal pigment epithelial cells
and fosters their replacement by a health population of
cells.36,38 Grid laser photocoagulation may also work simply
by destroying a certain population of photoreceptors, and
eliminating high oxygen consumers may result in an increase
in the level of inner retinal oxygen and a reduction in tissue
vascular endothelial growth factor, which has been impli-
cated in the development of macular edema.12,38
Anatomically, in Group 1; the CMT decreased from preop-
erative values with statistically significant reduction at all
postoperative intervals until 6 months (p < 0.01). There was
an average of 44.78% reduction in the mean CMT at the
2nd week and 34.67% reduction at the 6th month. In Group
2; the CMT decreased from preoperative values with statisti-
cally significant reduction at all postoperative intervals until
3 months (p < 0.01); but the difference in the mean CMT
between preoperative and postoperative 6th months was
not statistically significant (p > 0.05). So we found combined
IVTA and grid laser photocoagulation more successful in long
term. Some other studies also reported a significant reduc-
tion in CMT in patients undergoing phacoemulsification sur-
gery with intravitreal triamcinolone injection.4,5,20,32 Kang
et al. applied macular grid photocoagulation after intravitreal
triamcinolone acetonide for diffuse diabetic macular edema
and found the CMT less than the normal upper limit
(206 lm) after 6 months in 15 eyes of 44 eyes in the laser
group and 6 of 19 in the control group. Although the exact
mechanism underlying the maintenance of improved vision
Management of cataract in patients with diabetic macular edema 37and decreased central macular thickness due to grid laser
photocoagulation after IVTA was not precisely identified,
Kang et al., speculate that decreased foveal thickness after
IVTA facilitates the delivery of the laser energy selectively
to the photoreceptors and retinal pigment epithelia or ster-
oids might act beneficially in the process of mature laser scar
formation by suppressing inflammation caused by laser treat-
ment.12 DRCR-net study indicated that intravitreal steroid or
ranibizumab injections combined with laser treatment have a
superior effect on VA improvement than laser treatment
alone in diabetic macular edema (DME).39
There are other treatment options such as intravitreal
injections of antivascular endothelial growth factor (anti-
VEGF) drugs or pars plana vitrectomy for DME. Ranibizumab
and bevacizumab are the two main anti-VEGF drugs used
commonly. Although ranibizumab has been recently
approved by the United States Food and Drug Administra-
tion for the treatment of DME, it is expensive. Bevacizumab,
which costs much less than ranibizumab, is commonly used
off-label in treating DME.40–42 The results of studies compar-
ing IVTA and intravitreal bevacizumab (IVB) in DME are con-
troversial. Some studies found IVTA more effective than IVB,
some the same and some less effective. A meta analysis
shows that the group receiving IVTA has a statistically signif-
icant improvement in BCVA than the group receiving IVB in
the first 3 months. But the difference in BCVA was not
observed at 6 months. Also the side effects of IVTA such as
elevation of IOP, cataract formation and risk of endoph-
thalmitis cause limitations in their use.40
The recent study by Cheema et al. revealed that after
combined cataract surgery and intravitreal IVB, macular
edema progressed only in 5.71% patients while 45.45%
patients in control group.43 In the study by Wahab et al. it
was reported that both grid laser and IVB in the management
of cataract with macular edema due to diabetes mellitus and
hypertension had a success rate of 60.5% in approaching
visual acuity of 6/6.20 Ju Byung et al. compared the results
of diabetic patients undergoing PHACO surgery receiving
intraoperative IVB or not. They concluded that intravitreal
ranibizumab injection at cataract surgery may prevent the
postoperative worsening of macular edema and may improve
the final visual outcome.44
Intravitreal steroid sustained release devices are being
developed to achieve long-standing concentrations and less
side effects. After a three year follow-up an 15 letter
improvement of BCVA from baseline was detected in
22.2% of the patients receiving 0.7 mg Dexamethasone
implant (Ozurdex) and 18.4% of the patients receiving
0.35 mg dexamethasone implant. The mean average reduc-
tion in CMT was 111.6 lm and 107.9 lm in the 0.7 mg
and 0.35 mg dexamethasone implant receiving groups,
respectively.45
In conclusion, phacoemulsification combined with IVTA
injection improves the BCVA in diabetic patients with macu-
lar edema. This improvement is statistically significant. In
addition to this therapy macular grid laser photocoagulation
after surgery helps to preserve the improvement in BCVA
and the decrease in OCT values.Conflict of interest
The authors declared that there is no conflict of interest.References
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